Developing next generation medicines
that will lead the fight against cancer & inflammation
- Tenalisib, our differentiated PI3K δ/γ inhibitor is now in Ph1/2 solid tumor trials
- RP7214, our DHODH inhibitor, is in Covid-19 Ph2 trials, given its potential to limit RNA viral replication via host-directed mechanism
- Phase 1/1b trial of RP12146, our 2nd gen PARP 1/2 inhibitor is in progress across solid tumors with promising early signs of differentiation
The Rhizen Journey!
Our journey to be a leading biopharmaceutical company developing differentiated products through cutting-edge science and strategic partnerships started in 2008.
Novel programs targeting multiple hallmarks of cancer & inflammation
Assessing the safety and efficacy of our novel pipeline
Accumulated from dedicated research efforts for the last 12 years
We Are All In To Make It Possible
OUR PARTNERING STRATEGY
Flexible Global and Regional Approach
Progress in-house assets through clinical POC/Phase II and out-license to global partners for registration and commercialization across major markets
In-license differentiated small molecule pre-clinical/IND stage assets in the Precision Oncology, Immuno-Oncology settings
Explore co-development opportunities with assets that complement Rhizen programs